There remains a severe shortfall of medical oncologists who are capable of a comprehensive study of clinically-relevant problems with human specimens in the laboratory, successful design and conduct clinical trials to improve prevention, detection, and treatment of human cancer, and very importantly, the translation of fundamental knowledge from the bench to the clinic. The shortage of medical oncologists over the next ten years continues. M. D. Anderson Cancer Center is well-suited to host a comprehensive training program that has the capability to reduce the severity of this shortfall.
The specific aims and overall objectives of this program remain unchanged: to train and nurture medical oncology fellows to ensure they are equipped to become the next leaders in every aspect of academic medical oncology. The training program herein provides three research training tracks for medical oncologists. The first track, the clinician investigator track provides training focused on development and implementation of clinical trials and associated correlative studies. The second track is the physician/scientist track which provides training for laboratory-based oncology research. And the third track is our community-based research track which takes advantage of our institution's extensive programs in cancer control and prevention. Fellows who complete this training program will be eligible for certification in the subspecialties of medical oncology and/or hematology. In addition, they will be able to provide the best hematology and medical oncology care available and also develop and lead independent research programs, conduct hypothesis-driven research, communicate their research findings through public presentations and publications in peer-reviewed journals, and obtain peer-reviewed grant support for their work.
This goal of this program is to provide training for the next generation of medical oncologists to perform cancer research, develop new approaches to treat and prevent cancer, and to treat cancer patients and survivors.
|Maiti, Abhishek; Nemati-Shafaee, Maryam; Msaouel, Pavlos et al. (2017) Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. Clin Genitourin Cancer :|
|Kim, Dae Won; Haydu, Lauren E; Joon, Aron Y et al. (2017) Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients. Cancer 123:1372-1381|
|Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2017) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets :|
|Ragon, Brittany Knick; Kantarjian, Hagop; Jabbour, Elias et al. (2017) Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. Am J Hematol 92:7-11|
|Wagner, Michael J; Mitra, Rahul; McArthur, Mark J et al. (2017) Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). Mol Cancer Ther 16:1114-1123|
|Msaouel, Pavlos; Zurita, Amado J; Huang, Shixia et al. (2017) Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma. Oncotarget 8:42149-42158|
|Msaouel, Pavlos; Zhang, Miao; Tu, Shi-Ming (2017) Prolonged Remission of Upper Urinary Tract Urothelial Carcinoma With Prominent Choriocarcinomatous Differentiation: A Case Report. Clin Genitourin Cancer 15:e73-e77|
|Msaouel, Pavlos; Gralla, Richard J; Jones, Randy A et al. (2017) Key issues affecting quality of life and patient-reported outcomes in prostate cancer: an analysis conducted in 2128 patients with initial psychometric assessment of the prostate cancer symptom scale (PCSS). BMJ Support Palliat Care 7:308-315|
|Teegavarapu, Purnima S; Rao, Priya; Matrana, Marc R et al. (2017) Outcomes of Adults With Ewing Sarcoma Family of Tumors (ESFT) of the Kidney: A Single-Institution Experience. Am J Clin Oncol 40:189-193|
|Wagner, Michael J; Gopalakrishnan, Vancheswaran; Ravi, Vinod et al. (2017) Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist 22:1271-1277|
Showing the most recent 10 out of 124 publications